Transformational cell therapies for patients with serious diseases.
Koligo’s R&D is focused on technologies that would greatly improve patient access to cell/tissue transplant and improve the safety and efficacy of cell/tissue transplant products:
Culture of stromal vascular stem cells (SVF) and/or micro-vascular fragments (MVF) obtained from the recipient patient induces vascularization of the cells for transplant
Preliminary data indicate that culture of allogeneic islets with recipient SVF may reduce potential for host rejection of the transplant (“chimerize”)
Collagenase spheroids containing SVF/MVF and islets are scalable in production and provide a bio-degradable scaffold to deliver islets and allow for engraftment subcutaneously.